ReGen Biologics Enters New Markets in Poland and South Africa

ReGen Biologics (OTC: RGBI) recently initiated marketing for its
products, including the CMI(R) collagen meniscus implant in Poland and
in South Africa.

The market introduction in Poland occurred on November 12 with
three surgeries completed on two patients in the "Centrum Medycyny
Sportowej" in Warsaw. The surgeries were performed by Dr. Konrad
Slynarski, assisted by Dr. William Rodkey, D.V.M., Vail, Colorado.
ReGen will be working with Biocare Therapeutics Sp. z.o.o. in Poznan
to train surgeons and market the CMI throughout Poland.

In addition, twenty leading knee surgeons from South Africa
attended a CMI training event on November 16 at the Sports Science
Institute of South Africa in Cape Town. Training was conducted by Dr.
Koen Lagae from Antwerp, Belgium and Dr. William Rodkey. Following the
training activities the same group observed five live CMI surgeries,
which were performed at the "Vincent Palotti Hospital" in Cape Town by
Dr. Koen Lagae and by the local host Dr. Willem van der Merwe, again
assisted by Dr. Rodkey.

ReGen will be working with Doc Medical Solutions, located at the
Sport Science Institute in Cape Town, to train surgeons and market the
CMI throughout South Africa.

"We are pleased to make our CMI collagen meniscus implant
available to patients and surgeons in Poland and South Africa,
representing a combined population of 90 million people," commented
Marcel Kyburz, General Manager of ReGen Biologics AG.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen´s patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. ReGen´s first approved
product using its collagen scaffold technology is the CMI(R) meniscus
application, which is cleared for sale in Europe and other countries
and marketed through ReGen´s European subsidiary, ReGen Biologics AG.

ReGen has conducted the largest human clinical trial on an
arthroscopic meniscus procedure. The resulting database has unique
value in better understanding meniscus injuries. The company is
headquartered in Hackensack, NJ and manufactures its products in its
ISO Certified facility located in Redwood City, CA. For more
information on ReGen, visit www.regenbio.com.

This press release contains forward-looking statements within the
meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
current expectations and beliefs of the management of ReGen and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including those discussed in the Risk
Factors section of ReGen´s 2006 annual report on Form 10-K and
additional filings with the SEC. ReGen´s filings with the SEC are
available to the public at the Company´s website at
http://www.regenbio.com, from commercial document-retrieval services
and at the Web site maintained by the SEC at http://www.sec.gov.